Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03624374 · ClinicalTrials.gov registry record
Natural History Study of Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)
A clinical trial of Genetic Disease and White Matter Disease, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT03624374: Recruiting study of Genetic Disease and White Matter Disease, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
NCT03624374 is a study of Genetic Disease and White Matter Disease that is actively recruiting participants, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 100 participants, below the 2,558-participant average among 30 other Genetic Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03624374, a study of Genetic Disease and White Matter Disease, is actively recruiting participants, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, we will conduct retrospective chart and imaging reviews and prospective longitudinal virtual assessments of individuals with LBSL.
Primary Outcome
Participants will be asked to provide all prior neurological, developmental and genetics medical records and available neuroimaging studies. We will first confirm eligibility by review of MRI and DARS2 mutation analysis. We will determine information about disease duration, rate of symptom progression and prevalence of specific neurological symptoms and the level of disability. We have derived an MRI severity score by modifying a standard leukodystrophy MRI scoring system, referred to as the Lo
Conditions Studied
Study Locations (1)
Maryland
- Hugo Moser Center for Leukodystrophies - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2029-05 |
What NCT03624374 shows while recruiting
NCT03624374 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,558-participant average among 30 other Genetic Disease trials with a reported enrollment target (96% lower).
The record links to 6 conditions, with Genetic Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03624374 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03624374 about?
NCT03624374 is a clinical study titled "Natural History Study of Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)". In this study, we will conduct retrospective chart and imaging reviews and prospective longitudinal virtual assessments of individuals with LBSL.
What is the current status of trial NCT03624374?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2018-04-01. Estimated completion is 2029-05.
What conditions does trial NCT03624374 study?
This clinical trial studies the following conditions: Genetic Disease, White Matter Disease, Leukoencephalopathies, LBSL, Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation.
Who is sponsoring clinical trial NCT03624374?
This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03624374 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03624374's enrollment target sits among peer trials
100 20th of 30 higher than 11 of 30 other Genetic Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Diagnostic Odyssey: Whole Genome Sequencing (WGS)
RECRUITING
-
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI